

Noriomi Matsumura

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4556053/publications.pdf>

Version: 2024-02-01

85
papers

3,540
citations

201385

27
h-index

149479

56
g-index

94
all docs

94
docs citations

94
times ranked

5905
citing authors

#	ARTICLE	IF	CITATIONS
1	Lower systolic blood pressure levels in early pregnancy are associated with a decreased risk of early-onset superimposed preeclampsia in women with chronic hypertension: a multicenter retrospective study. <i>Hypertension Research</i> , 2022, 45, 135-145.	1.5	12
2	B7-H3 Suppresses Antitumor Immunity via the CCL2â€“CCR2â€“M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. <i>Cancer Immunology Research</i> , 2022, 10, 56-69.	1.6	49
3	Increasing our knowledge of germline variants. <i>International Cancer Conference Journal</i> , 2022, 11, 1-1.	0.2	1
4	Oncologic outcomes in elderly patients who underwent hysterectomy for endometrial cancer: a multi-institutional survey in Kinki District, Japan. <i>International Journal of Clinical Oncology</i> , 2022, , 1.	1.0	1
5	Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1001-1012.	1.0	8
6	Phase II study of niraparib in recurrent or persistent rare fraction of gynecologic malignancies with homologous recombination deficiency (JGOG2052). <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	4
7	The roles and limitations of bevacizumab in the treatment of ovarian cancer. <i>International Journal of Clinical Oncology</i> , 2022, 27, 1120-1126.	1.0	14
8	CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	48
9	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. <i>JCO Precision Oncology</i> , 2022, , .	1.5	18
10	Scientific evaluation of alleged findings in <sc>HPV</sc> vaccines: Molecular mimicry and mouse models of vaccineâ€“induced disease. <i>Cancer Science</i> , 2022, 113, 3313-3320.	1.7	4
11	Targeting Dormant Ovarian Cancer Cells<i>In Vitro</i>and in an<i>In Vivo</i>Mouse Model of Platinum Resistance. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 85-95.	1.9	6
12	A Novel Malignant Peritoneal Mesothelioma with <i>STRN</i> Exon 2 and <i>ALK</i> Exon 20: A Case Report and Literature Review. <i>Oncologist</i> , 2021, 26, 356-361.	1.9	7
13	Rare tumor subtypes diagnosed by molecular analysis. <i>International Cancer Conference Journal</i> , 2021, 10, 95.	0.2	0
14	Tumor Immune Microenvironment during Epithelialâ€“Mesenchymal Transition. <i>Clinical Cancer Research</i> , 2021, 27, 4669-4679.	3.2	138
15	From genetic analysis to precision medicine. <i>International Cancer Conference Journal</i> , 2021, 10, 159-159.	0.2	1
16	Frequent PIK3CA mutations in eutopic endometrium of patients with ovarian clear cell carcinoma. <i>Modern Pathology</i> , 2021, 34, 2071-2079.	2.9	5
17	Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types. <i>JCO Precision Oncology</i> , 2021, 5, 1270-1280.	1.5	9
18	PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma. <i>Cancer Science</i> , 2021, 112, 4627-4640.	1.7	15

#	ARTICLE	IF	CITATIONS
19	Strategies for the use of immune checkpoint inhibitors. International Cancer Conference Journal, 2021, 10, 265-265.	0.2	0
20	The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. Journal of Gynecologic Oncology, 2021, 32, e49.	1.0	26
21	Pitfall in the diagnosis of Lynch syndrome. International Cancer Conference Journal, 2021, 10, 1-1.	0.2	0
22	Characterization of patients that can continue conservative treatment for adenomyosis. BMC Women's Health, 2021, 21, 431.	0.8	1
23	Endometriosis-associated ovarian cancer occurs early during follow-up of endometrial cysts. International Journal of Clinical Oncology, 2020, 25, 51-58.	1.0	28
24	Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2020, 46, 868-875.	0.5	24
25	Intratumor heterogeneity and homologous recombination deficiency of high-grade serous ovarian cancer are associated with prognosis and molecular subtype and change in treatment course. Gynecologic Oncology, 2020, 156, 415-422.	0.6	28
26	Various therapeutic effects of immune checkpoint inhibitors. International Cancer Conference Journal, 2020, 9, 169-169.	0.2	0
27	Low-Grade Endometrial Stromal Sarcoma with a Nodule-in-Nodule Appearance in Preoperative Magnetic Resonance Images. Case Reports in Obstetrics and Gynecology, 2020, 2020, 1-7.	0.2	3
28	Superparamagnetic iron oxide as a tracer for sentinel lymph node detection in uterine cancer: a pilot study. Scientific Reports, 2020, 10, 7945.	1.6	11
29	A message from the new editor-in-chief. International Cancer Conference Journal, 2020, 9, 51-51.	0.2	0
30	Endometriosis-Associated Ovarian Cancer: The Origin and Targeted Therapy. Cancers, 2020, 12, 1676.	1.7	32
31	The perspectives of molecularly targeted therapies which this issue illustrates. International Cancer Conference Journal, 2020, 9, 101-101.	0.2	0
32	A case of left renal atrophy following the development of an infected giant retroperitoneal chylous cyst after laparoscopic para-aortic lymphadenectomy for endometrial cancer. International Cancer Conference Journal, 2020, 9, 203-206.	0.2	0
33	Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma. Scientific Reports, 2020, 10, 2757.	1.6	134
34	Anti-VEGF therapy resistance in ovarian cancer is caused by GM-CSF-induced myeloid-derived suppressor cell recruitment. British Journal of Cancer, 2020, 122, 778-788.	2.9	61
35	Mucinous adenocarcinoma, gastric type of the uterine cervix: clinical features and HER2 amplification. Medical Molecular Morphology, 2019, 52, 52-59.	0.4	25
36	Severe fatty liver of pregnancy requiring an extremely large amount of blood transfusion, surgery and transarterial embolization: A case report. Case Reports in Women's Health, 2019, 23, e00130.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Acquisition of a side population fraction augments malignant phenotype in ovarian cancer. <i>Scientific Reports</i> , 2019, 9, 14215.	1.6	11
38	Placental Sonic Hedgehog Pathway Regulates Fetal Growth via the IGF Axis in Preeclampsia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4239-4252.	1.8	17
39	Association between preterm delivery and bacterial vaginosis with or without treatment. <i>Scientific Reports</i> , 2019, 9, 509.	1.6	48
40	The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1). <i>Gynecologic Oncology</i> , 2019, 153, 312-319.	0.6	17
41	Clinical Determinants Affecting Indications for Surgery and Chemotherapy in Recurrent Ovarian Granulosa Cell Tumor. <i>Healthcare (Switzerland)</i> , 2019, 7, 145.	1.0	3
42	Differential Diagnosis of Uterine Leiomyoma and Uterine Sarcoma Using Magnetic Resonance Images: A Literature Review. <i>Healthcare (Switzerland)</i> , 2019, 7, 158.	1.0	26
43	VISTA expressed in tumour cells regulates T cell function. <i>British Journal of Cancer</i> , 2019, 120, 115-127.	2.9	133
44	Snail promotes ovarian cancer progression by recruiting myeloid-derived suppressor cells via CXCR2 ligand upregulation. <i>Nature Communications</i> , 2018, 9, 1685.	5.8	211
45	Efficacy of weekly administration of paclitaxel and carboplatin for advanced ovarian cancer patients with poor performance status. <i>International Journal of Clinical Oncology</i> , 2018, 23, 698-706.	1.0	7
46	Two cases of recurrent uterine cervical cancer with arterio-enteric fistula treated by femoro-femoral artery bypass in hybrid operation room. <i>International Cancer Conference Journal</i> , 2018, 7, 26-29.	0.2	1
47	Longitudinal changes in magnetic resonance imaging of malignant and borderline tumors associated with ovarian endometriotic cyst comparing with endometriotic cysts without arising malignancy. <i>European Journal of Radiology</i> , 2018, 105, 175-181.	1.2	8
48	Impaired Wnt5a signaling in extravillous trophoblasts: Relevance to poor placentation in early gestation and subsequent preeclampsia. <i>Pregnancy Hypertension</i> , 2018, 13, 225-234.	0.6	13
49	The effect of the type of dietary protein on the development of ovarian cancer. <i>Oncotarget</i> , 2018, 9, 23987-23999.	0.8	11
50	Exome Sequencing Landscape Analysis in Ovarian Clear Cell Carcinoma Shed Light on Key Chromosomal Regions and Mutation Gene Networks. <i>American Journal of Pathology</i> , 2017, 187, 2246-2258.	1.9	104
51	Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells. <i>Clinical Cancer Research</i> , 2017, 23, 587-599.	3.2	213
52	Adult granulosa cell tumors of the ovary: a retrospective study of 30 cases with respect to the expression of steroid synthesis enzymes. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e31.	1.0	12
53	Subtypes of Ovarian Cancer and Ovarian Cancer Screening. <i>Diagnostics</i> , 2017, 7, 12.	1.3	80
54	<i>Pneumocystis</i> Pneumonia in Non-HIV Pregnant Women Receiving Chemotherapy for Malignant Lymphoma: Two Case Reports. <i>Case Reports in Obstetrics and Gynecology</i> , 2017, 2017, 1-4.	0.2	3

#	ARTICLE	IF	CITATIONS
55	Update on rare epithelial ovarian cancers: based on the Rare Ovarian Tumors Young Investigator Conference. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e54.	1.0	20
56	Distinct preoperative clinical features predict four histopathological subtypes of high-grade serous carcinoma of the ovary, fallopian tube, and peritoneum. <i>BMC Cancer</i> , 2017, 17, 580.	1.1	14
57	Unenhanced region on magnetic resonance imaging represents tumor progression in uterine carcinosarcoma. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e62.	1.0	4
58	Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. <i>Medical Science Monitor</i> , 2017, 23, 826-833.	0.5	3
59	Effectiveness of adjuvant systemic chemotherapy for intermediate-risk stage IB cervical cancer. <i>Oncotarget</i> , 2017, 8, 106866-106875.	0.8	30
60	Clinical Efficacy of Ovarian Cancer Screening. <i>Journal of Cancer</i> , 2016, 7, 1311-1316.	1.2	9
61	Paradigm Shift in the Management Strategy for Epithelial Ovarian Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, e247-e257.	1.8	9
62	Groin lymph node detection and sentinel lymph node biopsy in vulvar cancer. <i>Journal of Gynecologic Oncology</i> , 2016, 27, e57.	1.0	10
63	Dual Faces of IFN γ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. <i>Clinical Cancer Research</i> , 2016, 22, 2329-2334.	3.2	309
64	Clinical efficacy of neoadjuvant chemotherapy with irinotecan (CPT-11) and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer. <i>Journal of International Medical Research</i> , 2016, 44, 346-356.	0.4	5
65	Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles. <i>Gynecologic Oncology</i> , 2016, 141, 49-56.	0.6	33
66	Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes. <i>American Journal of Pathology</i> , 2016, 186, 1103-1113.	1.9	71
67	Comprehensive assessment of the expression of the SWI/SNF complex defines two distinct prognostic subtypes of ovarian clear cell carcinoma. <i>Oncotarget</i> , 2016, 7, 54758-54770.	0.8	25
68	Suppression of <i>ABHD2</i> , identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer. <i>Oncotarget</i> , 2016, 7, 47620-47636.	0.8	28
69	Hepatocyte nuclear factor-1 β (HNF-1 β) promotes glucose uptake and glycolytic activity in ovarian clear cell carcinoma. <i>Molecular Carcinogenesis</i> , 2015, 54, 35-49.	1.3	57
70	Subendometrial enhancement and peritumoral enhancement for assessing endometrial cancer on dynamic contrast enhanced MR imaging. <i>European Journal of Radiology</i> , 2015, 84, 581-589.	1.2	28
71	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- κ B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. <i>Cancer Research</i> , 2015, 75, 5034-5045.	0.4	439
72	Abstract A25: Dysregulation of MYC via STAT1 promotes tumor progression in serous papillary endometrial cancer. , 2015, , .		0

#	ARTICLE	IF	CITATIONS
73	Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib. <i>Cancer Biology and Therapy</i> , 2014, 15, 22-25.	1.5	14
74	Recent Concepts of Ovarian Carcinogenesis: Type I and Type II. <i>BioMed Research International</i> , 2014, 2014, 1-11.	0.9	164
75	Epigenetic and genetic dispositions of ovarian carcinomas. <i>Oncoscience</i> , 2014, 1, 574-579.	0.9	13
76	PD-L1 on Tumor Cells Is Induced in Ascites and Promotes Peritoneal Dissemination of Ovarian Cancer through CTL Dysfunction. <i>Clinical Cancer Research</i> , 2013, 19, 1363-1374.	3.2	196
77	Laparoscopic pelvic lymphadenectomy in patients with early-stage endometrial cancer. <i>Japanese Journal of Gynecologic and Obstetric Endoscopy</i> , 2013, 29, 291-296.	0.0	0
78	The activated transforming growth factor β signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. <i>International Journal of Cancer</i> , 2012, 130, 20-28.	2.3	62
79	Ovarian clear cell carcinoma as a stress-responsive cancer: Influence of the microenvironment on the carcinogenesis and cancer phenotype. <i>Cancer Letters</i> , 2011, 310, 129-133.	3.2	37
80	Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling. <i>Cancer Science</i> , 2010, 101, 2658-2663.	1.7	32
81	Ovarian cancer in endometriosis: molecular biology, pathology, and clinical management. <i>International Journal of Clinical Oncology</i> , 2009, 14, 383-391.	1.0	139
82	Activated Local Immunity by CCL19-Transduced Embryonic Endothelial Progenitor Cells Suppresses Metastasis of Murine Ovarian Cancer. <i>Stem Cells</i> , 2009, 28, N/A-N/A.	1.4	42
83	Immunostimulatory effect of Fms-like tyrosine kinase 3 ligand on peripheral monocyte-derived dendritic cells and natural killer cells: utilization for ovarian cancer treatment. <i>Oncology Reports</i> , 2008, 19, 505-15.	1.2	7
84	Oncogenic Property of Acrogranin in Human Uterine Leiomyosarcoma: Direct Evidence of Genetic Contribution in In vivo Tumorigenesis. <i>Clinical Cancer Research</i> , 2006, 12, 1402-1411.	3.2	61
85	Changes in the Serum Levels of Human Chorionic Gonadotropin and the Pulsatility Index of Uterine Arteries during Conservative Management of Retained Adherent Placenta. <i>Journal of Obstetrics and Gynaecology Research</i> , 2000, 26, 81-87.	0.6	39